Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02432560 · ClinicalTrials.gov registry record
Safety and Durability of Sirolimus for Treatment of LAM
A clinical trial of Lymphangioleiomyomatosis, sponsored by University of Cincinnati.
- Recruiting
- Registry status
- 600
- Enrollment target
- 20
- Study locations
NCT02432560: Recruiting study of Lymphangioleiomyomatosis, sponsored by University of Cincinnati.
NCT02432560 is a study of Lymphangioleiomyomatosis that is actively recruiting participants, run by University of Cincinnati. The registered enrollment target is 600 participants, below the 770-participant average among 10 other Lymphangioleiomyomatosis trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02432560, a study of Lymphangioleiomyomatosis, is actively recruiting participants, sponsored by University of Cincinnati.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.
Primary Outcome
Symptoms and adverse events will be recorded
Conditions Studied
Interventions
- DRUG Sirolimus
- DRUG Everolimus
Study Locations (20)
Ohio
- University of Cincinnati - Cincinnati
- Cleveland Clinic - Cleveland
Texas
- University of Texas Southwestern Medical Center - Dallas
- University of Texas Health Center - Houston
California
- Stanford University Medical Center - Stanford
Colorado
- National Jewish Health - Denver
Florida
- Mayo Clinic Jacksonville - Jacksonville
Georgia
- Emory University School of Medicine - Atlanta
Illinois
- Loyola University Medical Center, Chicago - Maywood
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2015-03 |
| Est. Completion | 2025-07-31 |
What NCT02432560 shows while recruiting
NCT02432560 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 770-participant average among 10 other Lymphangioleiomyomatosis trials with a reported enrollment target (22% lower).
The record links to 1 condition, with Lymphangioleiomyomatosis appearing as the primary indexed condition, and to 2 interventions - of which Sirolimus is the first listed.
NCT02432560 names 20 study sites across 18 states, led by Ohio, Texas, California.
Frequently Asked Questions
What is clinical trial NCT02432560 about?
NCT02432560 is a clinical study titled "Safety and Durability of Sirolimus for Treatment of LAM". The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or wi...
What is the current status of trial NCT02432560?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2015-03. Estimated completion is 2025-07-31.
What conditions does trial NCT02432560 study?
This clinical trial studies the following conditions: Lymphangioleiomyomatosis.
What interventions are being tested in trial NCT02432560?
The interventions under investigation include: Sirolimus (DRUG), Everolimus (DRUG).
Who is sponsoring clinical trial NCT02432560?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02432560 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphangioleiomyomatosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02432560's enrollment target sits among peer trials
600 3rd of 10 higher than 8 of 10 other Lymphangioleiomyomatosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphangioleiomyomatosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
RECRUITING · Phase 1
-
TSC Biosample Repository and Natural History Database
RECRUITING
-
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
RECRUITING
-
Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)
RECRUITING · Phase 1
-
Study of the Disease Process of Lymphangioleiomyomatosis
RECRUITING
-
Feasibility of [11C]Acetate-PET in LAM and TSC
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia